Skip to main content

Table 5 Laboratory tests, treatment and prognosis of nineteen patients with anti-GABA-B receptor encephalitis

From: Clinical characteristics and prognostic analysis of anti-gamma-aminobutyric acid-B (GABA-B) receptor encephalitis in Northeast China

Case No.

Anti-GABA-B receptor antibodies

Other antibodies

CSF routine

Treatment

Follow-up period (months)

Outcomes

Initial mRS on admission

Follow-up mRS

Serum

CSF

Serum

CSF

WBC (× 106/L)

Protein (g/L)

ICU

Latency to immuno-therapy (days)

Immunotherapy

Antiepileptic therapy

Favorable-prognosis group

 1

+

+

8

0.36

+

70

MP

LEV

18

Cured

5

0

 2 (primary)

++

++

18

0.57

+

30

IVIG

LEV

    

 2 (recurrence)

+

+

18

0.74

7

IVIG+MP

17

Improved

4

1

 3

+

+

5

0.43

30

IVIG+MP

2

Improved

5

1

 4

+++

+++

103

0.53

16

MP

27

Improved

2

1

 5

++

++

42

0.39

+

18

IVIG

OXC

20

Cured

5

0

 6

+

+

4

0.44

15

IVIG+MP

VPA + LEV

8

Improved

2

1

 7

+

+

19

0.34

22

IVIG

5

Cured

2

0

 8

+

+

NMDAR+

7

0.39

3

Improved

4

1

 9

+

+

8

0.33

35

MP

CBZ

3

Improved

5

1

 10

+

+

34

1.09

17

IVIG

2

Improved

2

1

 11 (primary)

++

+

20

0

+

29

MP

OXC

    

 11 (recurrence)

+

+

6

0.24

 

LEV

27

Cured

3

0

Poor-prognosis group

 12

+

+

Hu+

43

0.39

+

15

IVIG

LEV

9

Death

4

6

 13 (primary)

+~++

+~++

CV2/CRMP5++

CV2/CRMP5+++

9

0.63

+

15

IVIG+MP

LEV

    

 13 (recurrence)

+

+

CV2/CRMP5+

CV2/CRMP5+

9

0.63

+

8

IVIG+MP

13

Death

5

6

 14

+++

+++

Hu+

Hu+

96

0.37

+

27

Death

5

6

 15

+++

++

7

0.37

+

12

IVIG+MP

OXC

25

Death

5

6

 16

+

+

13

0.39

+

12

Death

5

6

 17

++

++

21

0.49

+

13

IVIG+MP

LEV

20

Death

5

6

 18

+

+

13

0.29

+

LEV

3

Death

5

6

 19

+

+

31

0

+

5

IVIG+MP

OXC

9

Unchanged

5

5

  1. CSF, cerebrospinal fluid; WBC, white blood cell; mRS, modified Rankin scale; NMDAR, anti-N-methyl-D-aspartate receptor antibody; Hu, anti-Hu antibody; CV2/CRMP5, anti-CV2/CRMP5 antibody; MP, methylprednisolone; IVIG, intravenous immunogloblin; LEV, levetiracetam; OXC, oxcarbazepine; VPA, valproic acid; CBZ, carbamazepine